Skip to main
ABT

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 50%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is a diversified healthcare company, operating across four segments including Established Pharmaceuticals, Nutritionals, Diagnostics, and Medical Devices. The company has a strong product portfolio and pipeline in high-growth areas such as Diabetes, Structural Heart and Diagnostics, and is well positioned for accelerating growth in FY27. With a focus on sustainability and a strong cash generation, Abbott is highly attractive as a GARP large-cap medtech name, trading at ~14.5x'27E consensus EPS, lower than the peer group.

Bears say

Abbott Laboratories is heavily reliant on sales outside the United States, which exposes it to risks related to economic, competitive, and geopolitical events. Additionally, product safety concerns and product liability claims pose a significant risk to profitability, and the declining sales in the Nutritional Products segment indicate potential struggles in transitioning to a volume-driven growth strategy. Overall, these factors contribute to a negative outlook for Abbott's stock, with limited growth potential and potential for significant liabilities in the future.

Abbott Labs (ABT) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 50% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 18 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.